Immunotherapy in Sarcoma: Future Horizons

详细信息    查看全文

• 作者：Melissa Burgess ; Vikram Gorantla ; Kurt Weiss ; Hussein Tawbi
• 关键词：Soft tissue sarcoma ; Immunosurveillance ; Immunotherapy ; Programmed death ; 1 (PD ; 1) ; Tumor ; infiltrating lymphocyte (TIL) ; Immune checkpoint blockade
• 刊名：Current Oncology Reports
• 出版年：2015
• 出版时间：November 2015
• 年：2015
• 卷：17
• 期：11
• 全文大小：937 KB
• 参考文献：Papers of particular interest, published recently, have been highlighted as: -Of importance ?-Of major importance1.Burningham Z, Hashibe M, Spector L, et al. The epidemiology of sarcoma. Clin Sarcoma Res. 2012;2:14.PubMed Central CrossRef PubMed
  2.Siegel R, Ma J, Zou Z, et al. Cancer statistics, 2014. CA Cancer J Clin. 2014;64:9-9.CrossRef PubMed
  3.Howlader N, Noone A, Krapcho M, et al: SEER Cancer Statistics Review, 1975-2010, National Cancer Institute. Bethesda, MD, http://?seer.?cancer.?gov/?csr/-975_-010/-/span> , based on November 2012 SEER data submission, posted to the SEER web site, April 2013 2013
  4.Italiano A, Mathoulin-Pelissier S, Cesne AL, et al. Trends in survival for patients with metastatic soft-tissue sarcoma. Cancer. 2011;117:1049-4.CrossRef PubMed
  5.Grier HE, Krailo MD, Tarbell NJ, et al. Addition of ifosfamide and etoposide to standard chemotherapy for Ewing’s sarcoma and primitive neuroectodermal tumor of bone. N Engl J Med. 2003;348:694-01.CrossRef PubMed
  6.Nesbit Jr ME, Gehan EA, Burgert Jr EO, et al. Multimodal therapy for the management of primary, nonmetastatic Ewing’s sarcoma of bone: a long-term follow-up of the First Intergroup study. J Clin Oncol. 1990;8:1664-4.PubMed
  7.Gerber NK, Wexler LH, Singer S, et al. Adult rhabdomyosarcoma survival improved with treatment on multimodality protocols. Int J Radiat Oncol Biol Phys. 2013;86:58-3.PubMed Central CrossRef PubMed
  8.Coley WB. II. Contribution to the knowledge of sarcoma. Ann Surg. 1891;14:199-20.PubMed Central CrossRef PubMed
  9.Nauts HC, McLaren JR. Coley toxins—the first century. Adv Exp Med Biol. 1990;267:483-00.CrossRef PubMed
  10.Johnston BJ, Novales ET. Clinical effect of Coley’s toxin. II. A seven-year study. Cancer Chemother Rep. 1962;21:43-8.PubMed
  11.Lascelles BD, Dernell WS, Correa MT, et al. Improved survival associated with postoperative wound infection in dogs treated with limb-salvage surgery for osteosarcoma. Ann Surg Oncol. 2005;12:1073-3.CrossRef PubMed
  12.Jeys LM, Grimer RJ, Carter SR, et al. Post operative infection and increased survival in osteosarcoma patients: are they associated? Ann Surg Oncol. 2007;14:2887-5.CrossRef PubMed
  13.Sottnik JL, U'Ren LW, Thamm DH, et al. Chronic bacterial osteomyelitis suppression of tumor growth requires innate immune responses. Cancer Immunol Immunother. 2010;59:367-8.CrossRef PubMed
  14.Behnke NK, Alamanda VK, Song Y, et al. Does postoperative infection after soft tissue sarcoma resection affect oncologic outcomes? J Surg Oncol. 2014;109:415-0.CrossRef PubMed
  15.Burnet M. Immunological factors in the process of carcinogenesis. Br Med Bull. 1964;20:154-.PubMed
  16.Dunn GP, Old LJ, Schreiber RD. The three Es of cancer immunoediting. Annu Rev Immunol. 2004;22:329-0.CrossRef PubMed
  17.Carswell EA, Old LJ, Kassel RL, et al. An endotoxin-induced serum factor that causes necrosis of tumors. Proc Natl Acad Sci U S A. 1975;72:3666-0.PubMed Central CrossRef PubMed
  18.Sabel MS, Arora A, Su G, et al. Synergistic effect of intratumoral IL-12 and TNF-alpha microspheres: systemic anti-tumor immunity is mediated by both CD8+ CTL and NK cells. Surgery. 2007;142:749-0.CrossRef PubMed
  19.Guo QY, Yuan M, Peng J, et al. Antitumor activity of mixed heat shock protein/peptide vaccine and cyclophosphamide plus interleukin-12 in mice sarcoma. J Exp Clin Cancer Res. 2011;30:24.PubMed Central CrossRef PubMed
  20.Zhang L, Conejo-Garcia JR, Katsaros D, et al. Intratumoral T cells, recurrence, and survival in epithelial ovarian cancer. N Engl J Med. 2003;348:203-3.CrossRef PubMed
  21.Berghuis D, Santos SJ, Baelde HJ, et al. Pro-inflammatory chemokine-chemokine receptor interactions within the Ewing sarcoma microenvironment determine CD8(+) T-lymphocyte infiltration and affect tumour progression. J Pathol. 2011;223:347-7.CrossRef PubMed
  22.Matsuo T, Shimose S, Kubo T, et al. Extraskeletal osteosarcoma with partial spontaneous regression. Anticancer Res. 2009;29:5197-01.PubMed
  23.Brinkrolf P, Landmeier S, Altvater B, et al. A high proportion of bone marrow T cells with regulatory phenotype (CD4+CD25hiFoxP3+) in Ewing sarcoma patients is associated with metastatic disease. Int J Cancer. 2009;125:879-6.CrossRef PubMed
  24.Nakayama T, Tsuboyama T, Toguchida J, et al. Natural course of desmoid-type fibromatosis. J Orthop Sci. 2008;13:51-.CrossRef PubMed
  25.Noria S, Davis A, Kandel R, et al. Residual disease following unplanned excision of soft-tissue sarcoma of an extremity. J Bone Joint Surg Am. 1996;78:650-.PubMed
  26.Lewis JJ, Leung D, Espat J, et al. Effect of reresection in extremity soft tissue sarcoma. Ann Surg. 2000;231:655-3.PubMed Central CrossRef PubMed
  27.Tsukahara T, Kawaguchi S, Torigoe T, et al. Prognostic significance of HLA class I expression in osteosarcoma defined by anti-pan HLA class I monoclonal antibody, EMR8-5. Cancer Sci. 2006;97:1374-0.CrossRef PubMed
  28.
• 作者单位：Melissa Burgess (1) (4)
  Vikram Gorantla (2)
  Kurt Weiss (3) (4)
  Hussein Tawbi (1) (4)
  
  1. Division of Hematology/Oncology, Department of Medicine, School of Medicine, University of Pittsburgh, Pittsburgh, PA, USA
  4. Sarcoma Program, University of Pittsburgh Cancer Institute, 5150 Centre Avenue, Fifth Floor, Pittsburgh, PA, 15232, USA
  2. Medical Oncology, American Oncology Institute, Serilingampally, Hyderabad, TS, India
  3. Division of Musculoskeletal Oncology, Department of Orthopedic Surgery, University of Pittsburgh, Pittsburgh, PA, USA
  
• 刊物主题：Oncology;
• 出版者：Springer US
• ISSN：1534-6269

文摘

Immunologic approaches to cancer are over a century old. Over the years, the strategy has been fine-tuned from inciting infections in subjects to inhibiting negative regulatory signals from the innate immune system. Sarcomas are among the first tumors to be considered for immune interventions. From Coley’s toxin to cytokine-based therapies to adoptive cell therapy, there have been numerous immunotherapeutic investigations in this patient population. A promising strategy includes adoptive T cell therapy which has been studied in small cohorts of synovial sarcoma, a subtype that is known to widely express the cancer testis antigen, NY-ESO-1. Additionally, recent data in metastatic melanoma and renal cell carcinoma demonstrate the utility and tremendous efficacy of immune checkpoint blockade with increased rates of durable responses compared to standard therapies. Responses in traditionally “non-immunogenic-tumors, such as lung and bladder cancers, provide ample rationale for the study of immune checkpoint inhibitors in sarcoma. While immunotherapy has induced some responses in sarcomas, further research will help clarify optimal patient selection for future clinical trials and new combinatorial immunotherapeutic strategies. Keywords Soft tissue sarcoma Immunosurveillance Immunotherapy Programmed death-1 (PD-1) Tumor-infiltrating lymphocyte (TIL) Immune checkpoint blockade